AASLD 2012: Final Study Results Show Telaprevir Is Safe and Effective for HIV/HCV Coinfected Patients
- Details
- Category: HIV/HCV Coinfection
- Published on Monday, 12 November 2012 00:00
- Written by Liz Highleyman
HIV/HCV coinfected people treated with telaprevir (Incivek) triple therapy are significantly more likely to achieve sustained virological response, or a cure, than people treated with pegylated interferon/ribavirin alone, according to final results from Study 110 presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.
Liver Meeting Highlights: New Hep C Drugs, NAFLD, Liver Cancer, Acetaminophen Toxicity, Benefits of Coffee
- Details
- Category: Hepatitis B
- Published on Monday, 12 November 2012 00:00
- Written by Liz Highleyman
The American Association for the Study of Liver Diseases Liver Meeting is the premier annual U.S. conference on 
hepatology, covering all aspects of liver disease including viral hepatitis, fatty liver, hepatocellular carcinoma, and liver transplantation. Kicking off the meeting on Saturday, AASLD President Guadalupe Garcia-Tsao offered a media overview of some highlights selected from the more than 2000 abstracts to be presented during the week.
AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis
- Details
- Category: HCV Treatment
- Published on Monday, 12 November 2012 00:00
- Written by Liz Highleyman
The experimental hepatitis C drugs danoprevir and mericitabine, with or without pegylated interferon and ribavirin, showed good safety and efficacy in previously treated patients, according to findings from the MATTERHORN study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Another analysis from the same trial showed good outcomes for people with liver fibrosis.
AASLD 2012: High Rate of Response to Daclatasvir and Asunaprevir in Harder-to-treat Hep C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 12 November 2012 00:00
- Written by Keith Alcorn
Although an interferon-free combination of antiviral drugs developed by Bristol-Myers Squibb (BMS) to treat hepatitis C was highly effective in curing the infection in previous null responders with HCV genotype 1b infection, some new antiviral drugs may still need to be administered with interferon in harder-to-treat patients with genotype 1a, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) in Boston.
AASLD Liver Meeting Starts this Weekend in Boston
- Details
- Category: Hepatitis B
- Published on Friday, 09 November 2012 00:00
- Written by Liz Highleyman
The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting is underway, running November 9-13 at the Hynes Convention Center in Boston. The AASLD meeting each fall and the European Association for the Study of the Liver (EASL) International Liver Congress each spring are the premier events for presentation of the latest data on treatment for hepatitis B and C.
Web Design and Development by